Cargando…

ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer

We performed an open-label randomized controlled phase III study comparing treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus concomitant cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gebre-Medhin, Maria, Brun, Eva, Engström, Per, Haugen Cange, Hedda, Hammarstedt-Nordenvall, Lalle, Reizenstein, Johan, Nyman, Jan, Abel, Edvard, Friesland, Signe, Sjödin, Helena, Carlsson, Henrik, Söderkvist, Karin, Thomasson, Marcus, Zackrisson, Björn, Nilsson, Per
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771720/ https://www.ncbi.nlm.nih.gov/pubmed/33052757 http://dx.doi.org/10.1200/JCO.20.02072

Ejemplares similares

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Radiotherapy—Dose Escalated for Large Volume Primary Tumors—And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck—A Randomized Phase II Trial
por: Mercke, Claes, et al.
Publicado: (2023)

Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status
por: Wendt, Malin, et al.
Publicado: (2021)

Human papillomavirus and survival of patients per histological subsite of tonsillar squamous cell carcinoma
por: Haeggblom, Linnea, et al.
Publicado: (2018)

Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection
por: Axelsson, Lars, et al.
Publicado: (2017)

Distribution of sentinel nodes from parotid tumors–A feasibility study
por: Hammarstedt‐Nordenvall, Lalle, et al.
Publicado: (2023)

Treatment and outcome among patients with laryngeal squamous cell carcinoma in Stockholm—A population‐based study
por: Blomkvist, Rasmus, et al.
Publicado: (2023)

Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy
por: Adrian, Gabriel, et al.
Publicado: (2022)

Incidence of IP and risk of malignant transformation in the Swedish population 1960–2010
por: Elliot, Alexandra, et al.
Publicado: (2016)

No evidence for human papillomavirus having a causal role in salivary gland tumors
por: Haeggblom, Linnea, et al.
Publicado: (2018)

HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome
por: Näsman, Anders, et al.
Publicado: (2013)

Post-Treatment Neck Dissection of Tonsillar and Base of Tongue Squamous Cell Carcinoma in the Era of PET-CT, HPV, and p16
por: Landin, David, et al.
Publicado: (2022)

PET/MR versus PET/CT for locoregional staging of oropharyngeal squamous cell cancer
por: Flygare, Lennart, et al.
Publicado: (2022)

Impact of HPV in Oropharyngeal Cancer
por: Marklund, Linda, et al.
Publicado: (2011)

A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Bi-Cheng, et al.
Publicado: (2019)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
por: Takeshita, Naohiro, et al.
Publicado: (2022)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer
por: Rajpara, Raj S, et al.
Publicado: (2014)

Tonsillar Microbiota: a Cross-Sectional Study of Patients with Chronic Tonsillitis or Tonsillar Hypertrophy
por: Wu, Shengru, et al.
Publicado: (2021)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
por: Saigal, Kunal, et al.
Publicado: (2014)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Occupational risk variation of nasopharyngeal cancer in the Nordic countries
por: Carpén, Timo, et al.
Publicado: (2022)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score-matched Analysis
por: Wu, Li-Rong, et al.
Publicado: (2018)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
por: Aggarwal, Himani, et al.
Publicado: (2020)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
por: Guigay, Joël, et al.
Publicado: (2019)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Possible influence of mammographic density on local and locoregional recurrence of breast cancer
por: Eriksson, Louise, et al.
Publicado: (2013)

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus
por: Hurt, Christopher N, et al.
Publicado: (2011)

Sorption Behaviors of Light Lanthanides(III) (La(III), Ce(III), Pr(III), Nd(III)) and Cr(III) Using Nitrolite
por: Wójcik, Grzegorz
Publicado: (2020)

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)

Ultrasound risk marker variability in symptomatic carotid plaque: impact on risk reclassification and association with temporal variation pattern
por: Stenudd, Isak, et al.
Publicado: (2020)

The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials
por: Zhang, Li, et al.
Publicado: (2010)

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II–III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy
por: Chen, Xingxing, et al.
Publicado: (2018)

Organorhodium(III)- and Iridium(III)-Substituted 20-Tungstobismuthates(III) and -Antimonates(III), [(MCp*)(2)X(2)W(20)O(70)](10–) (M = Rh(III) and Ir(III); X = Bi(III) and Sb(III))
por: Mougharbel, Ali S., et al.
Publicado: (2021)

A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer
por: Chen, Yuhchyau, et al.
Publicado: (2013)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal Downstaging After Induction Chemotherapy and Surgery
por: Amini, Arya, et al.
Publicado: (2012)

Bioradiotherapy with Cetuximab May Reduce the Risk of Neck Node Relapse in Locoregionally Advanced Laryngeal Glottic Carcinoma: May HER1-Profile Be Useful in the Bioselection of Patients?
por: Almadori, Giovanni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_301nfpe3qfcvfvub7q15jea8lf